Poland· PL-100356870
Praxbind
A idarucizumab product containing idarucizumabum, registered in Poland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Idarucizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC V03AB37 (idarucizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Idarucizumab · ATC V03AB37
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Idarucizumabum
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Poland (PL)
- ATC code
- V03AB37
- ATC class
- Idarucizumab
- Defined daily dose
- 5 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991244002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idarucizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumPraxbind 2.5 g/50 mlBoehringer Ingelheim International
- CzechiaPRAXBINDBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- SpainPRAXBIND 2.5 G/50 ML SOLUCION INYECTABLE Y PARA PERFUSIONBoehringer Ingelheim International Gmbh
- FinlandPraxbindBoehringer Ingelheim International GmbH
- IrelandPraxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim International GmbH
- IcelandPraxbindBoehringer Ingelheim International GmbH*
- NorwayPraxbindBoehringer Ingelheim International GmbH
- SwedenPraxbind 50 mg/ml Injektions-/infusionsvätska, lösningBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Praxbind
- Liechtenstein · Praxbind
- Norway · Praxbind
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f4e64dc9-b63b-42ee-bc06-e0e3c30ff91a GET /v1/drugs/f4e64dc9-b63b-42ee-bc06-e0e3c30ff91a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań / do infuzji",
"source": "urpl",
"strength": "2,5 g/50 ml",
"packaging": "05909991244002 ¦ Rpz ¦ EU/1/15/1056/001 ¦ 111727\n2 fiol. 50 ml",
"substance": "Idarucizumabum 2,5 g/50 ml",
"common_name": "Idarucizumabum",
"pl_product_id": "100356870",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about idarucizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.